SYRS, US87184Q2066

Syros Pharmaceuticals stock carries a delisting legacy

Published on 10/07/2026 at 06:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syros Pharmaceuticals stock is tied to a February 28, 2025 Nasdaq delisting decision. The company planned March filings as it shifted into a wind-down.

SYRS, US87184Q2066, Illustration mit AI erstellt.

Syros Pharmaceuticals stock carries a delisting legacy that still defines the security on October 7, 2026. According to Edgechat, the company traded on Nasdaq under SYRS from 2016 until its board approved a voluntary delisting and wind-down in early 2025.

February 2025 changed the listing

The decisive date was February 28, 2025, when Syros approved the voluntary Nasdaq delisting, according to Edgechat. The decision followed the failure of the SELECT-MDS-1 Phase 3 trial of tamibarotene combined with azacitidine to meet its primary complete-response endpoint.

For investors, the important comparison is between Syros's Nasdaq period and its post-delisting status: the company moved from a listed biotechnology story to a wind-down structure in 2025. That change is more material than a short-term chart move because it alters how the security is viewed and traded.

Two March filings marked the transition

Syros planned to file Form 25 on or about March 10, 2025, followed by Form 15 on or about March 20, 2025, according to Edgechat. The planned Form 15 would begin the process of ending the company's reporting obligations under the cited wind-down framework.

The source also describes a budget approved by Oxford Finance and a planned 90-day period for deregistration to become effective. Those dates give the Syros story a clear sequence: board approval on February 28, the planned Form 25 around March 10, and the planned Form 15 around March 20, 2025.

Gene-control platform remains the business context

Syros's own website describes a drug-discovery platform built around gene expression, with programs aimed at cancers and monogenic diseases. The company site also lists tamibarotene programs and its SELECT-MDS-1 trial among its program materials, according to Syros Pharmaceuticals.

That scientific background explains the original investment case, while the 2025 delisting decision explains the stock's present status. Syros Pharmaceuticals stock is therefore best understood through its corporate transition and historical filing sequence rather than through a conventional Nasdaq earnings cycle.

Syros stock status

The February 28, 2025 delisting decision and the March 10 and March 20 filing milestones remain the central dated markers for Syros Pharmaceuticals stock. The company is identified by ISIN US87184Q2066 in a current October 2026 equities list, with USD as the quoted currency and Pharmaceuticals as the industry group.